Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00796445
Registration number
NCT00796445
Ethics application status
Date submitted
21/11/2008
Date registered
24/11/2008
Date last updated
5/03/2021
Titles & IDs
Public title
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
Query!
Scientific title
GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma
Query!
Secondary ID [1]
0
0
2008-002447-16
Query!
Secondary ID [2]
0
0
111482
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Melanoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Malignant melanoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - GSK 2132231A
Treatment: Drugs - Placebo
Experimental: MAGE-A3 Group - Patients who received up to 13 doses of recMAGE-A3 + AS15 ASCI. Study products were administered as intramuscular (IM) injections in the deltoid or the lateral region of the thigh (not in anatomical regions where lymph nodes had been excised): 5 doses of ASCI product at 3-week intervals, followed by 8 doses of ASCI product at 12-week intervals.
Placebo Comparator: Placebo Group - Patients who received up to 13 doses of placebo. Study products were administered as intramuscular (IM) injections in the deltoid or the lateral region of the thigh (not in anatomical regions where lymph nodes had been excised): 5 doses of placebo at 3-week intervals, followed by 8 doses of placebo at 12-week intervals.
Treatment: Drugs: GSK 2132231A
IM solution, a course of 13 injections administered over 27 months
Treatment: Drugs: Placebo
IM solution, a course of 13 injections administered over 27 months
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Disease Free Survival (DFS)
Query!
Assessment method [1]
0
0
DFS = time to event from randomization to the date of first disease recurrence (as assessed by investigator) or the date of death (whatever cause), whichever occurred first. DFS was expressed as the person-year rate i.e. the number of patients with at least one event (n) over the sum of the follow-up periods in years (T), until the first occurrence of a recurrence/death. Types of recurrence to be considered as an event included loco-regional and distant metastases. Any death occurring without prior documentation of tumor recurrence was considered as an event (not censored in the stat. analysis) as this approach was less prone to introduce bias. If no event occurred by the time of analysis, then the time to event was censored at the last assessment date (tumor assessment/visit) of the patient. Any new primary cancer at another site, including second primary melanoma, was not considered as a recurrence and had to be reported as a Serious Adverse Event (SAE).
Query!
Timepoint [1]
0
0
At Final analysis (Month 30 = Year 2.5)
Query!
Primary outcome [2]
0
0
Disease Free Survival (DFS)
Query!
Assessment method [2]
0
0
DFS = time to event from randomization to the date of first disease recurrence (as assessed by investigator) or the date of death (whatever cause), whichever occurred first. DFS was expressed as the person-year rate i.e. the number of patients with at least one event (n) over the sum of the follow-up periods in years (T), until the first occurrence of a recurrence/death. Types of recurrence to be considered as an event included loco-regional and distant metastases. Any death occurring without prior documentation of tumor recurrence was considered as an event (not censored in the stat. analysis) as this approach was less prone to introduce bias. If no event occurred by the time of analysis, then the time to event was censored at the last assessment date (tumor assessment/visit) of the patient. Any new primary cancer at another site, including second primary melanoma, was not considered as a recurrence and had to be reported as a Serious Adverse Event (SAE).
Query!
Timepoint [2]
0
0
At follow-up analysis (up to Year 5)
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
Overall Survival (OS) was defined as the time to event from randomization to the date of death, irrespective of the cause of death. OS was expressed as the person-year rate i.e. the number of patients with death (n) over the sum of the follow-up periods in years (T). Patients alive at the time of the analysis were censored on the date last known to be alive.
Query!
Timepoint [1]
0
0
At Final analysis (Month 30 = Year 2.5) and at follow-up analysis (up to Year 5)
Query!
Secondary outcome [2]
0
0
Disease-free Specific Survival (DFSS)
Query!
Assessment method [2]
0
0
Disease Free Specific Survival (DFSS) was defined as the time to event from randomization to the date of first recurrence of disease or date of death due to melanoma (cause as assessed by investigator), whichever occurred first. DFSS was expressed as the person-year rate i.e. the number of patients with at least one event (n) over the sum of the follow-up periods in years (T), until the first occurrence of a recurrence/death. Patients who died due to a cause other than the disease under study and patients alive at the time of analysis were censored on the date of last assessment (visit or tumor assessment).
Query!
Timepoint [2]
0
0
At Final analysis (Month 30 = Year 2.5)
Query!
Secondary outcome [3]
0
0
Distant Metastasis-free Survival (DMFS)
Query!
Assessment method [3]
0
0
Distant Metastasis Free Survival (DMFS) was defined as the time to event from randomization to the date of first distant metastasis or date of death, whichever occurred first. DMFS was expressed as the person-year rate i.e. the number of patients with at least one event (n) over the sum of the follow-up periods in years (T), until the first occurrence of distant metastasis/death. Patients alive and without distant metastases were censored at the date of last assessment (visit or tumor assessment, or date of last tumor assessment as documented during the yearly contact follow-up period).
Query!
Timepoint [3]
0
0
At Final analysis (Month 30 = Year 2.5)
Query!
Secondary outcome [4]
0
0
Health-related Quality of Life
Query!
Assessment method [4]
0
0
The assessment of health-related quality of life was restricted to patients who consented to study participation after Protocol Amendment 1 became effective at their study site, and for whom a validated version of the Euro Quality of Life-5D (EQ-5D) questionnaire was available in their native language. The EQ-5D comprises a 5-dimensional descriptive system (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), where each item has 3 levels and together they define 243 possible health states. For each health state, a value (utility) was determined by using an additive algorithm. These utility scores were calculated for each patient at each timepoint at which an EQ-5D questionnaire was completed. The score had a maximum value of 1.0 corresponding to full health level, while lower scores, down to a minimum value of 0.0 reflected degradation in the health-related quality of life.
Query!
Timepoint [4]
0
0
At Weeks 0, 6, 12 [on the day of and the day after treatment administration (TA)], at Month 6, 9, 12, 24, at the Concluding visit (Month 30) + 6 months and +12 Months and at disease recurrence
Query!
Secondary outcome [5]
0
0
Number of Subjects With Anti-MAGE-A3 Antibody Concentrations Above the Cut-off Value
Query!
Assessment method [5]
0
0
The cut-off value was 27 Enzyme-Linked Immunosorbent Assay (ELISA) units per milliliter (EL.U/mL).
Query!
Timepoint [5]
0
0
At Weeks 0, 6, 12, 36, 48 72, 120 (Concluding visit) and at Week 120 + 6 months
Query!
Secondary outcome [6]
0
0
Anti-MAGE-A3 Antibody Geometric Mean Concentrations
Query!
Assessment method [6]
0
0
Anti-MAGE-A3 antibody concentrations were presented as geometric mean concentrations (GMC) and expressed in EL.U/mL.
Query!
Timepoint [6]
0
0
At Weeks 0, 6, 12, 36, 48 72, 120 (Concluding visit) and at Month 120 + 6 months
Query!
Secondary outcome [7]
0
0
Number of Subjects With Anti-MAGE-A3 Antibody Response
Query!
Assessment method [7]
0
0
Treatment response defined as: - For initially seronegative patients: post-treatment antibody concentration = 27 EL.U/mL; - For initially seropositive patients: post-treatment antibody concentration = 2 fold the pre-treatment antibody concentration.
Query!
Timepoint [7]
0
0
At Weeks 6, 12, 36, 48 72, 120 (Concluding visit) and at Month 120 + 6 months
Query!
Secondary outcome [8]
0
0
Number of Subjects With Abnormal Haematological and Biochemical Parameters
Query!
Assessment method [8]
0
0
Laboratory abnormalities belong to hematological and biochemical parameters such as: alanine aminotransferase [ALT], asparatate aminostransferase [AST], alkaline phoshatase [AP], bilirubin [BIL], creatinine [CREA], hemoglobin [HGB], leukocytes [LEU], lymphopenia [LYMPH], neutrophils [NEU], platelets [PLA]. Parameter grades (Grade [G] 0, 1, 2, 3, 4, Unknown) were compared to each baseline parameter grade (G Unknown, 0, 1, 2, 3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 of August 9, 2006.
Query!
Timepoint [8]
0
0
Within the 31-day (Days 0-30) post-treatment period
Query!
Secondary outcome [9]
0
0
Number of Subjects With Any Adverse Events (AEs)
Query!
Assessment method [9]
0
0
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Query!
Timepoint [9]
0
0
Within the 31-day (Days 0-30) follow-up period after treatment
Query!
Secondary outcome [10]
0
0
Number of Subjects With Any Serious Adverse Events (SAEs)
Query!
Assessment method [10]
0
0
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Query!
Timepoint [10]
0
0
From Day 0 up to study end (up to 5 years)
Query!
Secondary outcome [11]
0
0
Number of Subjects With Potential Immune-mediated Diseases (pIMDs)
Query!
Assessment method [11]
0
0
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Query!
Timepoint [11]
0
0
From Day 0 up to study end (up to 5 years)
Query!
Eligibility
Key inclusion criteria
- Written informed consent signed.
- Male or female patient with histologically proven stage IIIB or IIIC cutaneous
melanoma presenting with macroscopic lymph node involvement suitable for surgery.
- The patient must have been surgically rendered free of disease before the
randomization.
- Patient is = 18 years old at the time of signing the informed consent form.
- The patient's lymph node tumor shows expression of the MAGE-A3 gene.
- The patient has fully recovered from surgery.
- ECOG performance status of 0 or 1 at the time of randomization.
- The patient must have adequate organ functions as assessed by standard laboratory
criteria.
- If the patient is female, she must be of non-childbearing potential, or practice
adequate contraception.
- In the opinion of the investigator, the patient can and will comply with all the
requirements of the protocol.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- The patient suffers from a mucosal or ocular melanoma.
- The patient has or has had any history of in-transit metastases
- The patient has been treated or is scheduled to be treated with an adjuvant anticancer
therapy after the surgery that qualifies the patient for inclusion in the present
trial.
- The patient requires concomitant chronic treatment with systemic corticosteroids or
any other immunosuppressive agents.
- Use of any investigational or non-registered product (drug or vaccine) other than the
study treatment.
- The patient has a history of autoimmune disease.
- The patient has a family history of congenital or hereditary immunodeficiency.
- The patient is known to be positive for Human Immunodeficiency Virus (HIV) or has
another confirmed or suspected immunosuppressive or immunodeficient condition.
- History of allergic disease or reactions likely to be exacerbated by any component of
the treatments.
- The patient has psychiatric or addictive disorders that may compromise his/her ability
to give informed consent or to comply with the trial procedures.
- The patient has concurrent severe medical problems, unrelated to the malignancy, that
would significantly limit full compliance with the study or expose the patient to
unacceptable risk.
- The patient has previous or concomitant malignancies at other sites, except
effectively treated non-melanoma skin cancers or carcinoma in situ of the cervix or
effectively treated malignancy that has been in remission for over 5 years and is
highly likely to have been cured.
- The patient has an uncontrolled bleeding disorder.
- For female patients: the patient is pregnant or lactating.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
27/01/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1351
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Camperdown
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - North Sydney
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Waratah
Query!
Recruitment hospital [4]
0
0
GSK Investigational Site - Westmead
Query!
Recruitment hospital [5]
0
0
GSK Investigational Site - Brisbane
Query!
Recruitment hospital [6]
0
0
GSK Investigational Site - Adelaide
Query!
Recruitment hospital [7]
0
0
GSK Investigational Site - Hobart
Query!
Recruitment hospital [8]
0
0
GSK Investigational Site - East Melbourne
Query!
Recruitment hospital [9]
0
0
GSK Investigational Site - Heidelberg
Query!
Recruitment postcode(s) [1]
0
0
2060 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2060 - North Sydney
Query!
Recruitment postcode(s) [3]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [4]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [5]
0
0
4102 - Brisbane
Query!
Recruitment postcode(s) [6]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [7]
0
0
7000 - Hobart
Query!
Recruitment postcode(s) [8]
0
0
3002 - East Melbourne
Query!
Recruitment postcode(s) [9]
0
0
3084 - Heidelberg
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kentucky
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Louisiana
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maryland
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Massachusetts
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Michigan
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Minnesota
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Missouri
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Nevada
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New Jersey
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New York
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
North Carolina
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Ohio
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Oregon
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Pennsylvania
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
South Carolina
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Tennessee
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Texas
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Utah
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Virginia
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Washington
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
West Virginia
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Wisconsin
Query!
Country [32]
0
0
Argentina
Query!
State/province [32]
0
0
Buenos Aires
Query!
Country [33]
0
0
Argentina
Query!
State/province [33]
0
0
Río Negro
Query!
Country [34]
0
0
Argentina
Query!
State/province [34]
0
0
Santa Fe
Query!
Country [35]
0
0
Argentina
Query!
State/province [35]
0
0
Ciudad Autónoma de Buenos Aires
Query!
Country [36]
0
0
Austria
Query!
State/province [36]
0
0
Feldkirch
Query!
Country [37]
0
0
Austria
Query!
State/province [37]
0
0
Graz
Query!
Country [38]
0
0
Austria
Query!
State/province [38]
0
0
Linz
Query!
Country [39]
0
0
Austria
Query!
State/province [39]
0
0
Salzburg
Query!
Country [40]
0
0
Austria
Query!
State/province [40]
0
0
Wels
Query!
Country [41]
0
0
Austria
Query!
State/province [41]
0
0
Wien
Query!
Country [42]
0
0
Belgium
Query!
State/province [42]
0
0
Bruxelles
Query!
Country [43]
0
0
Belgium
Query!
State/province [43]
0
0
Liège
Query!
Country [44]
0
0
Belgium
Query!
State/province [44]
0
0
Wilrijk
Query!
Country [45]
0
0
Brazil
Query!
State/province [45]
0
0
Minas Gerais
Query!
Country [46]
0
0
Brazil
Query!
State/province [46]
0
0
Rio Grande Do Sul
Query!
Country [47]
0
0
Brazil
Query!
State/province [47]
0
0
São Paulo
Query!
Country [48]
0
0
Bulgaria
Query!
State/province [48]
0
0
Plovdiv
Query!
Country [49]
0
0
Bulgaria
Query!
State/province [49]
0
0
Sofia
Query!
Country [50]
0
0
Canada
Query!
State/province [50]
0
0
Manitoba
Query!
Country [51]
0
0
Canada
Query!
State/province [51]
0
0
Ontario
Query!
Country [52]
0
0
Czechia
Query!
State/province [52]
0
0
Brno
Query!
Country [53]
0
0
Czechia
Query!
State/province [53]
0
0
Hradec Kralove
Query!
Country [54]
0
0
Czechia
Query!
State/province [54]
0
0
Ostrava
Query!
Country [55]
0
0
Czechia
Query!
State/province [55]
0
0
Praha 10
Query!
Country [56]
0
0
Czechia
Query!
State/province [56]
0
0
Praha 2
Query!
Country [57]
0
0
Estonia
Query!
State/province [57]
0
0
Tallinn
Query!
Country [58]
0
0
Estonia
Query!
State/province [58]
0
0
Tartu
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Besançon cedex
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Bordeaux
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Boulogne
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Brest
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Dijon
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Grenoble
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Le Mans
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Lille
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Limoges cedex
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Marseille Cedex 5
Query!
Country [69]
0
0
France
Query!
State/province [69]
0
0
Montpellier
Query!
Country [70]
0
0
France
Query!
State/province [70]
0
0
Nantes
Query!
Country [71]
0
0
France
Query!
State/province [71]
0
0
Nice
Query!
Country [72]
0
0
France
Query!
State/province [72]
0
0
Paris Cedex 10
Query!
Country [73]
0
0
France
Query!
State/province [73]
0
0
Paris
Query!
Country [74]
0
0
France
Query!
State/province [74]
0
0
Pierre-Bénite cedex
Query!
Country [75]
0
0
France
Query!
State/province [75]
0
0
Poitiers
Query!
Country [76]
0
0
France
Query!
State/province [76]
0
0
Reims
Query!
Country [77]
0
0
France
Query!
State/province [77]
0
0
Rennes
Query!
Country [78]
0
0
France
Query!
State/province [78]
0
0
Rouen
Query!
Country [79]
0
0
France
Query!
State/province [79]
0
0
Saint-Etienne
Query!
Country [80]
0
0
France
Query!
State/province [80]
0
0
Toulouse cedex 9
Query!
Country [81]
0
0
France
Query!
State/province [81]
0
0
Tours
Query!
Country [82]
0
0
France
Query!
State/province [82]
0
0
Villejuif
Query!
Country [83]
0
0
Germany
Query!
State/province [83]
0
0
Baden-Wuerttemberg
Query!
Country [84]
0
0
Germany
Query!
State/province [84]
0
0
Bayern
Query!
Country [85]
0
0
Germany
Query!
State/province [85]
0
0
Hessen
Query!
Country [86]
0
0
Germany
Query!
State/province [86]
0
0
Mecklenburg-Vorpommern
Query!
Country [87]
0
0
Germany
Query!
State/province [87]
0
0
Niedersachsen
Query!
Country [88]
0
0
Germany
Query!
State/province [88]
0
0
Nordrhein-Westfalen
Query!
Country [89]
0
0
Germany
Query!
State/province [89]
0
0
Rheinland-Pfalz
Query!
Country [90]
0
0
Germany
Query!
State/province [90]
0
0
Saarland
Query!
Country [91]
0
0
Germany
Query!
State/province [91]
0
0
Sachsen-Anhalt
Query!
Country [92]
0
0
Germany
Query!
State/province [92]
0
0
Sachsen
Query!
Country [93]
0
0
Germany
Query!
State/province [93]
0
0
Schleswig-Holstein
Query!
Country [94]
0
0
Germany
Query!
State/province [94]
0
0
Thueringen
Query!
Country [95]
0
0
Germany
Query!
State/province [95]
0
0
Berlin
Query!
Country [96]
0
0
Greece
Query!
State/province [96]
0
0
Athens
Query!
Country [97]
0
0
Ireland
Query!
State/province [97]
0
0
Cork
Query!
Country [98]
0
0
Ireland
Query!
State/province [98]
0
0
Dublin
Query!
Country [99]
0
0
Ireland
Query!
State/province [99]
0
0
Galway
Query!
Country [100]
0
0
Israel
Query!
State/province [100]
0
0
Haifa
Query!
Country [101]
0
0
Israel
Query!
State/province [101]
0
0
Petach Tikva
Query!
Country [102]
0
0
Israel
Query!
State/province [102]
0
0
Ramat Gan
Query!
Country [103]
0
0
Italy
Query!
State/province [103]
0
0
Campania
Query!
Country [104]
0
0
Italy
Query!
State/province [104]
0
0
Emilia-Romagna
Query!
Country [105]
0
0
Italy
Query!
State/province [105]
0
0
Friuli-Venezia-Giulia
Query!
Country [106]
0
0
Italy
Query!
State/province [106]
0
0
Lazio
Query!
Country [107]
0
0
Italy
Query!
State/province [107]
0
0
Liguria
Query!
Country [108]
0
0
Italy
Query!
State/province [108]
0
0
Lombardia
Query!
Country [109]
0
0
Italy
Query!
State/province [109]
0
0
Puglia
Query!
Country [110]
0
0
Italy
Query!
State/province [110]
0
0
Toscana
Query!
Country [111]
0
0
Italy
Query!
State/province [111]
0
0
Veneto
Query!
Country [112]
0
0
Japan
Query!
State/province [112]
0
0
Shizuoka
Query!
Country [113]
0
0
Japan
Query!
State/province [113]
0
0
Tokyo
Query!
Country [114]
0
0
Korea, Republic of
Query!
State/province [114]
0
0
Seoul
Query!
Country [115]
0
0
Mexico
Query!
State/province [115]
0
0
Nuevo León
Query!
Country [116]
0
0
Netherlands
Query!
State/province [116]
0
0
Nijmegen
Query!
Country [117]
0
0
Netherlands
Query!
State/province [117]
0
0
Rotterdam
Query!
Country [118]
0
0
New Zealand
Query!
State/province [118]
0
0
Auckland
Query!
Country [119]
0
0
New Zealand
Query!
State/province [119]
0
0
Christchurch
Query!
Country [120]
0
0
New Zealand
Query!
State/province [120]
0
0
Wellington
Query!
Country [121]
0
0
Norway
Query!
State/province [121]
0
0
Oslo
Query!
Country [122]
0
0
Poland
Query!
State/province [122]
0
0
Bydgoszcz
Query!
Country [123]
0
0
Poland
Query!
State/province [123]
0
0
Gdansk
Query!
Country [124]
0
0
Poland
Query!
State/province [124]
0
0
Kraków
Query!
Country [125]
0
0
Poland
Query!
State/province [125]
0
0
Olsztyn
Query!
Country [126]
0
0
Poland
Query!
State/province [126]
0
0
Poznan
Query!
Country [127]
0
0
Poland
Query!
State/province [127]
0
0
Slupsk
Query!
Country [128]
0
0
Poland
Query!
State/province [128]
0
0
Warszawa
Query!
Country [129]
0
0
Romania
Query!
State/province [129]
0
0
Baia Mare
Query!
Country [130]
0
0
Romania
Query!
State/province [130]
0
0
Cluj-Napoca
Query!
Country [131]
0
0
Romania
Query!
State/province [131]
0
0
Craiova, Dolj
Query!
Country [132]
0
0
Russian Federation
Query!
State/province [132]
0
0
Chelyabinsk
Query!
Country [133]
0
0
Russian Federation
Query!
State/province [133]
0
0
Kursk
Query!
Country [134]
0
0
Russian Federation
Query!
State/province [134]
0
0
Moscow
Query!
Country [135]
0
0
Russian Federation
Query!
State/province [135]
0
0
Omsk
Query!
Country [136]
0
0
Russian Federation
Query!
State/province [136]
0
0
St. Petersburg
Query!
Country [137]
0
0
Russian Federation
Query!
State/province [137]
0
0
Stavropol
Query!
Country [138]
0
0
Serbia
Query!
State/province [138]
0
0
Belgrad
Query!
Country [139]
0
0
Serbia
Query!
State/province [139]
0
0
Sremska Kamenica
Query!
Country [140]
0
0
Spain
Query!
State/province [140]
0
0
Barcelona
Query!
Country [141]
0
0
Spain
Query!
State/province [141]
0
0
Madrid
Query!
Country [142]
0
0
Spain
Query!
State/province [142]
0
0
Pamplona
Query!
Country [143]
0
0
Spain
Query!
State/province [143]
0
0
Sevilla
Query!
Country [144]
0
0
Spain
Query!
State/province [144]
0
0
Valencia
Query!
Country [145]
0
0
Sweden
Query!
State/province [145]
0
0
Göteborg
Query!
Country [146]
0
0
Sweden
Query!
State/province [146]
0
0
Malmö
Query!
Country [147]
0
0
Sweden
Query!
State/province [147]
0
0
Uppsala
Query!
Country [148]
0
0
Switzerland
Query!
State/province [148]
0
0
Basel
Query!
Country [149]
0
0
Switzerland
Query!
State/province [149]
0
0
Zürich
Query!
Country [150]
0
0
Taiwan
Query!
State/province [150]
0
0
Kaohsiung
Query!
Country [151]
0
0
Taiwan
Query!
State/province [151]
0
0
Taipei
Query!
Country [152]
0
0
Taiwan
Query!
State/province [152]
0
0
Taoyuan Hsien
Query!
Country [153]
0
0
Ukraine
Query!
State/province [153]
0
0
Dnipropetrovsk
Query!
Country [154]
0
0
Ukraine
Query!
State/province [154]
0
0
Donetsk
Query!
Country [155]
0
0
Ukraine
Query!
State/province [155]
0
0
Krivoy Rog
Query!
Country [156]
0
0
Ukraine
Query!
State/province [156]
0
0
Kyiv
Query!
Country [157]
0
0
Ukraine
Query!
State/province [157]
0
0
Lviv
Query!
Country [158]
0
0
United Kingdom
Query!
State/province [158]
0
0
Essex
Query!
Country [159]
0
0
United Kingdom
Query!
State/province [159]
0
0
Belfast, Northern Ireland
Query!
Country [160]
0
0
United Kingdom
Query!
State/province [160]
0
0
Colchester
Query!
Country [161]
0
0
United Kingdom
Query!
State/province [161]
0
0
Dundee
Query!
Country [162]
0
0
United Kingdom
Query!
State/province [162]
0
0
London
Query!
Country [163]
0
0
United Kingdom
Query!
State/province [163]
0
0
Poole, Dorset
Query!
Country [164]
0
0
United Kingdom
Query!
State/province [164]
0
0
Salisbury
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this clinical trial is to evaluate the benefit of the immunotherapeutic
product GSK 2132231A in preventing disease relapse when given to melanoma patients, after
surgical removal of their tumor.
This Protocol Posting has been updated following Amendments 1 of the Protocol, March 2010.
The impacted sections are outcome measures and entry criteria.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00796445
Query!
Trial related presentations / publications
Dreno B, Thompson JF, Smithers BM, Santinami M, Jouary T, Gutzmer R, Levchenko E, Rutkowski P, Grob JJ, Korovin S, Drucis K, Grange F, Machet L, Hersey P, Krajsova I, Testori A, Conry R, Guillot B, Kruit WHJ, Demidov L, Thompson JA, Bondarenko I, Jaroszek J, Puig S, Cinat G, Hauschild A, Goeman JJ, van Houwelingen HC, Ulloa-Montoya F, Callegaro A, Dizier B, Spiessens B, Debois M, Brichard VG, Louahed J, Therasse P, Debruyne C, Kirkwood JM. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Jul;19(7):916-929. doi: 10.1016/S1470-2045(18)30254-7. Epub 2018 Jun 13.
Dizier B, Callegaro A, Debois M, Dreno B, Hersey P, Gogas HJ, Kirkwood JM, Vansteenkiste JF, Sequist LV, Atanackovic D, Goeman J, van Houwelingen H, Salceda S, Wang F, Therasse P, Debruyne C, Spiessens B, Brichard VG, Louahed J, Ulloa-Montoya F. A Th1/IFNgamma Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 Apr 1;26(7):1725-1735. doi: 10.1158/1078-0432.CCR-18-3717. Epub 2019 Nov 15.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00796445
Download to PDF